![](https://tracker.live.rns-distribution.com/track.live-rns/3964258_75d1671758db0ed18eba2dbba83793b2.png)
Instem plc
("Instem" or "the Company")
Holding(s) in Company
As previously announced, on 19 April 2021 DWTH Holdings, Inc ("DWTH") notified the Company of its interest in 868,203 Ordinary Shares of ten pence each in the capital of the Company ("Ordinary Shares"). These Ordinary Shares were issued to DWTH as part of the consideration for the acquisition of d-Wise Technologies, Inc ("d-Wise") which legally completed on 1 April 2021.
On 30 April 2021, DWTH confirmed to the Company that, as intended, registered ownership of these Ordinary Shares had been transferred to the two d-Wise founding shareholders and 16 other d-wise shareholders. Accordingly, DWTH no longer has in interest in Ordinary Shares.
A Standard form for notification of major holdings (TR1) can be found at the foot of this announcement.
For further information, please contact:
Instem plc | Via Walbrook |
Phil Reason, CEO |
|
Nigel Goldsmith, CFO |
|
|
|
N+1 Singer (Nominated Adviser & Broker) | +44 (0) 20 7496 3000 |
Peter Steel Alex Bond Rachel Hayes |
|
|
|
Walbrook Financial PR | +44 (0) 20 7933 8780 |
Tom Cooper | instem@walbrookpr.com |
Nick Rome Nicholas Johnson |
|
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 600 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i | ||||||
| ||||||
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: | Instem plc | |||||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||||
Non-UK issuer | | |||||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||||
An acquisition or disposal of voting rights | X | |||||
An acquisition or disposal of financial instruments | | |||||
An event changing the breakdown of voting rights | | |||||
Other (please specify) iii: | | |||||
3. Details of person subject to the notification obligation iv | ||||||
Name | DWT Holdings, Inc | |||||
City and country of registered office (if applicable) | Asheville, USA | |||||
4. Full name of shareholder(s) (if different from 3.) v | ||||||
Name | | |||||
City and country of registered office (if applicable) | | |||||
5. Date on which the threshold was crossed or reached vi: | 30/04/2021 | |||||
6. Date on which issuer notified (DD/MM/YYYY): | 04/05/2021 | |||||
7. Total positions of person(s) subject to the notification obligation | ||||||
| % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments | Total of both in % (8.A + 8.B) | Total number of voting rights held in issuer (8.A + 8.B) vii | ||
Resulting situation on the date on which threshold was crossed or reached | - | - | - | - | ||
Position of previous notification (if applicable) | 3.99% | - | 3.99% | 868,203 | ||
8. Notified details of the resulting situation on the date on which the threshold was crossed or reached viii | |||||||||
A: Voting rights attached to shares | |||||||||
Class/type of ISIN code (if possible) | Number of voting rights ix | % of voting rights | |||||||
Direct (DTR5.1) | Indirect (DTR5.2.1) | Direct (DTR5.1) | Indirect (DTR5.2.1) | ||||||
Ordinary GB00B3TQCK30 | | | | | |||||
| | | | | |||||
| | | | | |||||
SUBTOTAL 8. A | | | |||||||
| |||||||||
B 1: Financial Instruments according to DTR5.3.1R (1) (a) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | |||||
| | | | | |||||
| | | | | |||||
| | | | | |||||
| | SUBTOTAL 8. B 1 | | | |||||
| |||||||||
B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b) | |||||||||
Type of financial instrument | Expiration | Exercise/ | Physical or cash Settlement xii | Number of voting rights | % of voting rights | ||||
| | | | | | ||||
| | | | | | ||||
| | | | | | ||||
| | | SUBTOTAL 8.B.2 | | | ||||
| |||||||||
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X") | ||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | X | |||
Full chain of controlled undertakings through which the voting rights and/or the | | |||
Name xv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| ||||
10. In case of proxy voting, please identify: | ||||
Name of the proxy holder | N/A | |||
The number and % of voting rights held | N/A | |||
The date until which the voting rights will be held | N/A | |||
| ||||
11. Additional information xvi | ||||
| ||||
Place of completion | Off-market |
Date of completion | 30/04/2021 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.